Showing results (701-710 of 782) with videos related to
Sort By:
Pageof 79
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.Blood|November 23, 2006
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myelomaYazan Alsayed, Hai Ngo, Judith Runnels, et al.Blood Cancer Discovery|October 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3Mariateresa Fulciniti, Yao Yao, Tommaso Perini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working GroupMeletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.Blood|December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setAjai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.Blood|January 14, 2009
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyAbdel Kareem Azab, Judith M Runnels, Costas Pitsillides, et al.Pageof 79